New small molecules in dermatology: for the autoimmunity, inflammation and beyond
Objective and design The discovery of new inflammatory pathways and the mechanism of action of inflammatory, autoimmune, genetic, and neoplastic diseases led to the development of immunologically driven drugs. We aimed to perform a narrative review regarding the rising of a new class of drugs capable of blocking important and specific intracellular signals in the maintenance of these pathologies: the small molecules. Materials/methods A total of 114 scientific papers were enrolled in this narrative review. Results We describe in detail the families of protein kinases—Janus Kinase (JAK), Src kinase, Syk tyrosine kinase, Mitogen-Activated Protein Kinase (MAPK), and Bruton Tyrosine Kinase (BTK)—their physiologic function and new drugs that block these pathways of intracellular signaling. We also detail the involved cytokines and the main metabolic and clinical implications of these new medications in the field of dermatology. Conclusions Despite having lower specificity compared to specific immunobiological therapies, these new drugs are effective in a wide variety of dermatological diseases, especially diseases that had few therapeutic options, such as psoriasis, psoriatic arthritis, atopic dermatitis, alopecia areata, and vitiligo..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
Inflammation research - 72(2023), 6 vom: 22. Mai, Seite 1257-1274 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Criado, Paulo Ricardo [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Atopic |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00011-023-01744-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2143954433 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2143954433 | ||
| 003 | DE-627 | ||
| 005 | 20240118092600.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00011-023-01744-w |2 doi | |
| 035 | |a (DE-627)OLC2143954433 | ||
| 035 | |a (DE-He213)s00011-023-01744-w-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Criado, Paulo Ricardo |e verfasserin |0 (orcid)0000-0001-9785-6099 |4 aut | |
| 245 | 1 | 0 | |a New small molecules in dermatology: for the autoimmunity, inflammation and beyond |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Objective and design The discovery of new inflammatory pathways and the mechanism of action of inflammatory, autoimmune, genetic, and neoplastic diseases led to the development of immunologically driven drugs. We aimed to perform a narrative review regarding the rising of a new class of drugs capable of blocking important and specific intracellular signals in the maintenance of these pathologies: the small molecules. Materials/methods A total of 114 scientific papers were enrolled in this narrative review. Results We describe in detail the families of protein kinases—Janus Kinase (JAK), Src kinase, Syk tyrosine kinase, Mitogen-Activated Protein Kinase (MAPK), and Bruton Tyrosine Kinase (BTK)—their physiologic function and new drugs that block these pathways of intracellular signaling. We also detail the involved cytokines and the main metabolic and clinical implications of these new medications in the field of dermatology. Conclusions Despite having lower specificity compared to specific immunobiological therapies, these new drugs are effective in a wide variety of dermatological diseases, especially diseases that had few therapeutic options, such as psoriasis, psoriatic arthritis, atopic dermatitis, alopecia areata, and vitiligo. | ||
| 650 | 4 | |a Dermatitis | |
| 650 | 4 | |a Atopic | |
| 650 | 4 | |a Janus kinases | |
| 650 | 4 | |a Src-family kinases | |
| 650 | 4 | |a Syk Kinase | |
| 650 | 4 | |a Mitogen-activated protein kinase kinases | |
| 700 | 1 | |a Lorenzini, Daniel |0 (orcid)0000-0002-6850-5799 |4 aut | |
| 700 | 1 | |a Miot, Hélio Amante |0 (orcid)0000-0002-2596-9294 |4 aut | |
| 700 | 1 | |a Bueno-Filho, Roberto |0 (orcid)0000-0003-2871-0306 |4 aut | |
| 700 | 1 | |a Carneiro, Francisca Regina Oliveira |0 (orcid)0000-0001-6735-4004 |4 aut | |
| 700 | 1 | |a Ianhez, Mayra |0 (orcid)0000-0003-3604-3128 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammation research |d Springer International Publishing, 1995 |g 72(2023), 6 vom: 22. Mai, Seite 1257-1274 |w (DE-627)182632229 |w (DE-600)1221794-3 |w (DE-576)045152705 |x 1023-3830 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2023 |g number:6 |g day:22 |g month:05 |g pages:1257-1274 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00011-023-01744-w |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_2018 | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2023 |e 6 |b 22 |c 05 |h 1257-1274 | ||